Modification of xenogenic bone substitute materials - effects on the early healing cascadein vitro

6533b7d1fe1ef96bd125c452

RESEARCH PRODUCT

Modification of xenogenic bone substitute materials - effects on the early healing cascadein vitro

Florian G. Draenert Eik Schiegnitz Peer W. Kämmerer Peer W. Kämmerer Wilfried Wagner Abdulmonem Alshihri

subject

Vascular Endothelial Growth Factor A medicine.medical_specialty medicine.medical_treatment Enzyme-Linked Immunosorbent Assay In Vitro Techniques Biomimetic Materials Transforming Growth Factor beta In vivo Internal medicine medicine Humans Platelet Platelet activation Bone regeneration Platelet-Derived Growth Factor Minerals Wound Healing biology Platelet Count Chemistry Platelet Activation In vitro Insulin-Like Growth Factor Binding Protein 1 Cytokine Endocrinology Bone Substitutes Immunology biology.protein Cytokines Collagen Oral Surgery Wound healing Platelet-derived growth factor receptor

description

Introduction Initial platelet activation with subsequent cytokine release at the defect site plays a crucial role in tissue integration. The aim of this study was to evaluate the influence of topographic and biomimetic collagen modifications of a xenogenic bone substitute material (BSM) on in vitro platelet activation and cytokine release. Material and Methods Three types of xenogenic BSM were used. Two BSM with different levels of granularity (large granule BSM [XBSM/L], small granule BSM [XBSM/S]) and a BSM with collagen (XBSM/C). All three samples were incubated with platelet concentrate of four healthy volunteers at room temperature for 15 min. For all groups, highly thrombogenic collagen type 1 served as a reference and an additional preparation with platelet concentrate only (without XBSM) served as control. Platelet count and cytokine release of VEGF, PDGF, TGF-β, and IGF into the supernatant were measured. Results Compared with the control group, XBSM/C showed an increase in platelets consumption (mean 41,000 ± 26,000/ml vs. 471,000 ± 38,000/ml), cytokine release of VEGF (mean 46.8 ± 7.2 pg/ml vs. 18.8 ± 2.7 pg/ml), and PDGF (mean 18,350 ± 795 pg/ml vs. 2726 ± 410 pg/ml) but not IGF (194,728 ± 51,608 pg/ml vs. 1,333,911 ± 35,314 pg/ml). There was also an increase in cytokine release of TGF-s in XBSM/C compared with XBSM/S (77,188 ± 27,413 pg/ml vs. 38,648 ± 13,191 pg/ml), but no such difference when compared with XBSM/L (77,188 ± 27,413 pg/ml vs. 53,309 ± 29,430 pg/ml). XBSM/L showed higher platelets consumption (301,000 ± 45,000 vs. 415,000 ± 98,000) and a higher cytokine release of PDGF (3511 ± 247 pg/ml vs. 3165 ± 78 pg/ml) compared with XBSM/S. There was no distinct difference in the levels of VEGF, TGF-s, and IGF between XBSM/L and XBSM/S. Conclusions Topographic as well as biomimetic modifications of the xenogenic BSM showed an increased platelet activation and cytokine release in vitro. This effect on the intrinsic healing cascade could result in comparable enhanced soft- and hard-tissue regeneration in vivo.

year	journal	country	edition	language
2013-03-31	Clinical Oral Implants Research

https://doi.org/10.1111/clr.12153